Building the intelligence layer for longer, healthier and more productive lives

QLS–ABI Longevity™ and the New Longevity Economy

8/23/202615 min read

man and woman sitting on bench facing sea

Author: Trang Phan

Executive summary

The world is entering a demographic and economic transition that will reshape healthcare, insurance, employment, financial services, housing, consumer technology and public policy: people are living longer, while societies are increasingly asking whether those additional years can also be healthier, more independent and more productive. The scale of the shift is substantial. The World Health Organization estimates that the global population aged 60 and above will increase from roughly 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050; by 2030, approximately one in six people globally will be 60 or older, while the number of people aged 80 and above is expected to reach 426 million by 2050. (World Health Organization) At the same time, consumer spending around health and wellbeing is already operating at enormous scale. The Global Wellness Institute estimates that the global wellness economy reached US$6.8 trillion in 2024, representing approximately 6.1% of global GDP, after growing 7.9% in a single year; it has doubled since 2013 and is forecast to reach approximately US$9.8 trillion by 2029, growing around 7.6% annually. For perspective, GWI estimates that wellness is already larger than global tourism at roughly US$5 trillion, information technology at US$5.3 trillion and pharmaceuticals at US$1.8 trillion, while representing around 60% of the approximately US$11.2 trillion spent globally on health. (Global Wellness Institute) This does not mean that the entire wellness economy is a longevity market; it is not. It does demonstrate that trillions of dollars are already flowing into many of the activities that determine how well people age. Against this backdrop, QLS–ABI Longevity™, developed by Trang Phan, proposes a strategic shift: longevity should not be viewed only through medicine, genetics, supplements or wearable devices, but also through an intelligence layer that helps make sense of the growing amount of information produced by the human body over time. The original QLS–ABI framework describes this as an information and biological-logic layer and proposes applications ranging from personal health monitoring to preventive healthcare and national longevity infrastructure. Put more simply, today's health system is becoming increasingly good at collecting information about people; the next opportunity is becoming much better at understanding what that information means, identifying meaningful change early and helping people and healthcare professionals decide what to do next. That is the strategic space in which QLS–ABI Longevity™ is positioned.

1. Longevity is becoming one of the world's largest structural economic themes

The longevity opportunity begins with a simple fact: the world is not merely adding more people; it is adding more years of human life. WHO expects the number of people aged 60 and above to more than double between 2020 and 2050, with approximately two-thirds of the world's over-60 population living in low- and middle-income countries by mid-century. (World Health Organization) This changes the economic question. For much of the twentieth century, societies were organized around a relatively predictable life sequence: education, several decades of work and a comparatively short retirement. Longer lives stretch every part of that model. People may work longer, retrain more often, consume healthcare for longer periods, require different housing, save differently, purchase different insurance products and spend considerably more on maintaining physical and mental capability. Governments face the same transition through healthcare budgets, pensions, social care and workforce participation. Longevity therefore cannot be understood simply as an anti-ageing industry. It is better understood as an emerging economic system around longer human lives. WHO explicitly notes that population ageing requires changes across healthcare and social care as well as transportation, housing and urban planning. (World Health Organization) The commercial opportunity consequently extends from hospitals and pharmaceuticals into insurance, financial services, food, fitness, consumer technology, housing, workplace design, education, travel and digital services.

2. The money is already moving toward health, prevention and wellbeing

The size and growth of the wellness economy provide one of the clearest indicators of changing consumer priorities. Global wellness spending reached US$6.8 trillion in 2024, having doubled since 2013. Over the longer 2013–2024 period, GWI estimates wellness spending grew approximately 6.5% annually, compared with approximately 3.2% annual growth in global GDP. The industry is forecast to grow another 7.6% annually through 2029, reaching approximately US$9.8 trillion and potentially representing around 7.1% of the world economy. (Global Wellness Institute) Some categories are expanding even faster. Wellness real estate grew approximately 19.5% annually from 2019 to 2024, while mental wellness expanded approximately 12.4% annually; GWI expects wellness real estate to grow approximately 15.8% annually through 2029, mental wellness around 10.1%, and traditional and complementary medicine around 10.8%. (Global Wellness Institute) The geographical opportunity is also broad. The United States represented an estimated US$2.1 trillion wellness market in 2024, China approximately US$950 billion, Germany US$281 billion, Japan US$262 billion, the United Kingdom US$261 billion and India US$180 billion. India grew approximately 11.3% annually between 2019 and 2024, while Saudi Arabia grew around 12.2%. Indonesia, already a US$56 billion wellness economy, demonstrates the scale that can emerge in Southeast Asian markets. (Global Wellness Institute) These numbers reinforce a central strategic point: longevity does not need to create consumer demand from zero. The demand already exists across multiple categories; the opportunity is to connect currently fragmented spending into better health outcomes.

3. The current market is fragmented around pieces of the human health journey

Today's longevity market contains sophisticated companies, but most operate on individual pieces of the problem. Pharmaceutical and biotechnology companies study ageing mechanisms and develop therapies. Diagnostics companies measure blood, genetics and other biomarkers. Wearables monitor sleep, movement, heart rate and recovery. Nutrition companies focus on food and supplements. Fitness companies target physical performance. Hospitals diagnose and treat disease. Insurance companies manage financial risk. Digital-health platforms organize medical information. Artificial intelligence increasingly helps analyze these datasets. The original QLS–ABI Longevity™ framework groups the landscape into biological, chemical, device and information layers. The useful insight is not that these industries are incomplete; each performs an important function. The strategic gap is that measurement is expanding faster than understanding. A smartwatch can produce thousands of observations. A laboratory can produce dozens or hundreds of biomarkers. Medical records can contain years of clinical history. Genetic tests can produce enormous datasets. The problem increasingly becomes how to determine which changes matter, which are normal, which deserve attention, how different signals relate to one another and when an individual should act.

4. QLS–ABI Longevity™ is designed around that missing intelligence layer

QLS–ABI Longevity™ proposes that the next generation of longevity systems should do more than collect health data: they should help interpret the changing condition of a person over time. In everyday language, imagine the difference between a dashboard and a navigation system. A dashboard tells you your speed, fuel level and engine temperature. A navigation system understands where you are, where you are going, whether conditions are changing and what action may be appropriate. Much of today's consumer health technology remains closer to the dashboard. It can tell someone how long they slept, how many steps they walked, their resting heart rate or the result of a laboratory test. The longer-term QLS–ABI proposition is to move toward navigation: understanding a person's normal baseline, recognizing when several indicators begin changing together, separating temporary fluctuations from persistent changes and helping determine whether the appropriate response is simply to monitor, change behavior, obtain another measurement or consult a healthcare professional. That distinction is potentially important because the economic value of health data does not come primarily from generating more numbers; it comes from making those numbers useful.

5. The opportunity is to move healthcare from snapshots toward a continuous picture

Most healthcare still operates through snapshots. A person visits a doctor, undergoes tests and receives a picture of their health at that moment. Months or years may pass before another picture is taken. Connected devices create the possibility of something different: a continuous or near-continuous view of selected aspects of health. This matters because change can sometimes be more informative than a single number. A person's resting heart rate, sleep pattern or activity level might individually remain within a broad population range while changing significantly relative to that person's own history. The reverse is also possible: a measurement that looks unusual relative to the population may be normal and stable for a particular individual. The future of personalized health therefore depends increasingly on understanding your normal, how your normal changes and whether multiple changes together indicate something worth investigating. QLS–ABI's proposed intelligence layer is designed around that longitudinal view rather than treating every measurement as an isolated event.

6. The biggest economic prize is healthier years, not simply more years

The commercial language around longevity sometimes focuses on extending lifespan, but the more immediate economic opportunity is healthspan—the period of life during which people remain healthy and capable. The difference is fundamental. An additional decade of life accompanied by substantial disability has a different value for the individual, family, healthcare system and economy than an additional decade in which someone remains mobile, cognitively capable, socially engaged and relatively independent. This reframes longevity from an extreme scientific objective into a much broader economic objective: help millions of people remain healthier for longer. The beneficiaries extend beyond consumers. Employers benefit when experienced workers remain capable. Insurers benefit if preventable high-cost events decline. Healthcare systems benefit when problems are identified earlier and managed more efficiently. Families benefit when older relatives retain independence. Governments benefit when healthy-life expectancy grows closer to total life expectancy. The market opportunity is therefore considerably larger than anti-ageing medicine alone.

7. Artificial intelligence could become the interpreter—but should not become an unquestioned medical authority

AI is particularly relevant because the amount of available health information is becoming too large and complex for individuals to interpret manually. A future health-intelligence platform could combine information from wearables, medical records, laboratory results, lifestyle patterns and other approved sources and help identify changes that deserve attention. But this is also where discipline matters. Detecting a pattern does not prove what caused it. Predicting risk does not automatically identify the correct treatment. A consumer application should not turn uncertain signals into medical certainty. QLS–ABI is therefore most credible when positioned as a health-intelligence and decision-support architecture, with stronger medical claims introduced only when clinical evidence supports them. The original document uses more ambitious language around correcting biological logic and self-maintaining longevity. Those ideas should currently be treated as the framework's long-term research vision rather than established medical capability.

8. Prevention could become one of the largest value pools—but savings must be demonstrated

The original QLS–ABI thesis argues for shifting spending away from waiting until disease becomes expensive and toward earlier detection and prevention. Strategically, the direction is compelling. Global health expenditure is already enormous: GWI's comparison places total worldwide health spending at approximately US$11.2 trillion, while wellness spending is already approximately 60% of that amount. (Global Wellness Institute) Even relatively small improvements in preventing or delaying expensive chronic conditions could therefore create significant economic value. But prevention is not automatically cheaper. More monitoring can create more tests, false alarms and unnecessary treatment. A successful QLS–ABI deployment would need to prove that earlier information leads to better decisions and that those decisions produce sufficiently better outcomes to justify their cost. The source's earlier estimates—including the proposition that a low-cost application might generate around US$1,000 per year in healthcare savings—should therefore be treated as targets for validation, not guaranteed savings.

9. The platform opportunity is much larger than a consumer longevity app

A consumer application could be the starting point, but the strategic architecture described by QLS–ABI potentially reaches much further. At the individual level, the system could help people understand changes in their health. At the healthcare level, it could help professionals see a clearer longitudinal picture between appointments. At the insurer level, appropriately governed preventive programs could potentially support earlier intervention. At the employer level, aggregated and privacy-protected insights might help improve workplace health programs without exposing individual medical information. At the research level, longitudinal datasets could improve understanding of how health changes across populations. At the government level, aggregated information could potentially support public-health planning. The original framework goes further by proposing national longevity data infrastructure and eventually a National Biological Integrity Index. That ambition is strategically interesting but would require very high standards for scientific validity, privacy, consent, cybersecurity, fairness and restrictions on how biological information could be used.

10. Data could become the strategic asset—but trust determines whether that asset can exist

The longevity sector may eventually discover that its most valuable asset is not a particular AI model but high-quality information about how human health changes over time. AI models can increasingly be replaced or upgraded. Longitudinal datasets linked to reliable outcomes are much harder to recreate. A platform that follows consenting individuals for years could potentially learn which patterns precede deterioration, which interventions work for which populations and which measurements provide little useful information. That creates a powerful learning advantage. But health data is among the most sensitive information a person can provide. A platform cannot build durable advantage by sacrificing trust. Consumers need to understand what is collected, why it is collected, who can access it and whether they can remove it. Employers should not gain unrestricted visibility into employee biology. Insurers should not automatically be able to use wellness signals to discriminate between customers. Governments should not convert preventive-health infrastructure into unrestricted biological surveillance. In longevity, privacy is not merely compliance; it is part of the product.

11. Vietnam has unusually strong reasons to take longevity seriously now

Vietnam's opportunity is particularly important because the country is ageing rapidly while still developing its digital economy and healthcare infrastructure. The country's demographic transition means that decisions made during the current decade could shape healthcare and economic performance for decades afterward. The original QLS–ABI paper identifies Vietnam as a potential development and deployment environment for longevity technology. The logic is stronger when framed around demographic urgency rather than national branding: Vietnam has the opportunity to build preventive and digital-health infrastructure before population ageing reaches its mature stage, rather than attempting to retrofit the system afterward. This creates a window for experimentation with digital health records, remote monitoring, preventive-care programs, healthy-ageing services and carefully governed health-data infrastructure.

12. Southeast Asia could become an important longevity market in its own right

The global wellness statistics also suggest that Asia should not be treated merely as a lower-cost development location for technologies ultimately sold in Western markets. China already represents approximately US$950 billion in wellness spending, Japan approximately US$262 billion, India US$180 billion, South Korea US$119 billion, Indonesia US$56 billion, the Philippines US$47 billion and Thailand US$43 billion. (Global Wellness Institute) These markets have very different demographic structures and healthcare systems, but collectively they demonstrate substantial regional demand for health and wellness products. As Asian societies age and household incomes rise, services around prevention, healthy ageing, home health, diagnostics, fitness, nutrition, financial planning and assisted living are likely to become increasingly interconnected. A QLS–ABI platform developed and validated in Vietnam could therefore eventually address a regional market rather than a single-country opportunity—but regional expansion should follow demonstrated clinical and commercial performance rather than precede it.

13. The winning business model is likely to connect several existing markets rather than invent an entirely new one

One of the strongest features of the QLS–ABI thesis is that it does not require longevity to become an entirely separate consumer category. The infrastructure could potentially connect markets that already exist. Wearables provide measurements. Laboratories provide biomarkers. Healthcare providers provide clinical interpretation and intervention. Nutrition and fitness businesses provide behavioral services. Insurers carry financial risk. Employers finance health benefits. Governments operate health infrastructure. AI provides analytical capability. QLS–ABI's potential role is the connecting intelligence layer between those pieces. This is strategically more attractive than competing directly with every device manufacturer, laboratory or healthcare provider. A platform business can potentially benefit from improvements across the ecosystem rather than needing to manufacture every component itself.

14. The strongest competitive advantage will come from evidence, not technology claims

Longevity is attracting substantial attention, which means ambitious claims are becoming common. The companies that ultimately create durable value are likely to be those that can demonstrate measurable results. For QLS–ABI, this means moving deliberately from concept to evidence. Can the platform accurately identify meaningful changes? Can those signals be reproduced? Can they predict outcomes that matter? Can people or clinicians act on them? Do those actions improve health? Do improvements persist? Are they safe across different age groups, sexes and populations? Do they reduce total healthcare costs or merely shift spending? Each question creates a higher standard of proof. The original QLS–ABI document suggests potential outcomes including 5–10 additional biological years, 20–30% lower health-insurance costs, 40% lower burnout and 1.2–1.5 percentage points of additional annual potential GDP. Those numbers should not currently be presented as expected results. They are better transformed into research goals that can be tested independently. If even a portion can eventually be demonstrated through credible studies, the commercial implications would be substantial.

15. National scale should come only after smaller-scale proof

The original roadmap envisages a 10,000-person pilot, followed by nationwide expansion and eventually a Vietnam Longevity Index and ASEAN expansion. The basic progression remains attractive, but expansion should depend on evidence rather than dates. The first phase should establish whether the system can collect reliable information and maintain engagement. The next should establish whether it can identify meaningful health changes. The following stage should test whether acting on those insights improves outcomes. Only after those questions are answered should insurers, employers, hospitals or national systems consider deeper integration. This approach reduces financial risk, protects users and makes eventual international expansion considerably more credible. The objective is not to deploy fastest; it is to learn fastest without compromising trust or safety.

16. The long-term opportunity is an operating layer for healthy longevity

The most ambitious interpretation of QLS–ABI is therefore not "another longevity app." It is an intelligence infrastructure for healthy ageing. Devices would collect selected signals. Laboratories and medical systems would add deeper health information. Individuals would contribute lifestyle and contextual information where appropriate. AI would help identify meaningful changes. Healthcare professionals would remain responsible for decisions requiring medical judgment. Researchers would use appropriately governed information to improve understanding. Over time, the system could become better at recognizing what healthy ageing looks like for different individuals rather than assuming that everyone should conform to one population average. That creates a fundamentally different product proposition: not simply telling people how old they appear biologically, but helping them understand what is changing, what may matter and what they can responsibly do about it.

17. The addressable opportunity extends far beyond healthcare

If people remain healthier for longer, value can potentially appear across multiple industries. Healthcare may avoid some expensive complications. Insurers may improve preventive programs. Employers may retain experienced workers longer. Financial-services companies may redesign savings and retirement products around longer lives. Housing developers may create homes and communities designed for ageing populations. Consumer companies may build products for older but active customers rather than treating ageing primarily as disability. Education providers may serve people through multiple career cycles. Travel, fitness, nutrition and wellness businesses may serve customers well beyond traditional retirement ages. WHO's demographic projections make clear that population ageing requires adaptation across society, not simply hospitals. (World Health Organization) The longevity economy is therefore best understood as a horizontal economic transformation affecting many industries simultaneously.

18. The strategic prize is not immortality—it is capability

The longevity sector can become distracted by extreme narratives about reversing ageing or dramatically extending human lifespan. The larger and more immediate economic opportunity is more practical: helping billions of people preserve physical capability, mental capability, independence and quality of life for longer. WHO projects 2.1 billion people aged 60 and above by 2050, creating a population roughly twice today's size living through later-life stages. (World Health Organization) If technology can help even part of that population remain healthier and independent for longer, the consequences extend through healthcare costs, workforce participation, household wealth, caregiving requirements and consumer demand. This is why longevity could become one of the defining economic themes of the coming decades even without a revolutionary anti-ageing therapy.

19. QLS–ABI should therefore be positioned around a simple promise

The strongest version of the QLS–ABI story is surprisingly straightforward. Healthcare has more information about the human body than ever before, but much of that information remains fragmented, difficult to interpret and used too late. QLS–ABI Longevity™ proposes an intelligence layer designed to help turn continuous health information into earlier understanding and better decisions. That positioning is easier to understand, easier to test and more commercially credible than claiming that software can directly "repair biological logic." It also creates a natural development path: first understand information, then demonstrate prediction, then demonstrate useful intervention, and only then make stronger claims about improving healthspan or reducing economic burden.

20. Strategic conclusion: a large market exists; the next challenge is converting data into better human outcomes

Three forces are now converging. First, the world is ageing: the population aged 60 and above is expected to rise to 1.4 billion by 2030 and 2.1 billion by 2050. Second, consumers are already spending at extraordinary scale on health and wellbeing: the wellness economy reached US$6.8 trillion in 2024 and is forecast to approach US$9.8 trillion by 2029, having doubled since 2013. Third, the technology required to observe human health is becoming increasingly available: wearables, diagnostics, connected healthcare systems and AI are producing a much richer picture of individual health than was previously possible. (World Health Organization) The unresolved problem is what to do with all that information. QLS–ABI Longevity™, authored by Trang Phan, is positioned around that gap. Its central proposition is that the longevity economy needs not only better medicines, better devices and more data, but a better intelligence layer capable of understanding how a person's health changes over time and helping translate those changes into responsible action. The commercial potential is significant because the surrounding markets already operate at trillion-dollar scale; the societal potential is larger because the ageing of the global population will affect almost every major economy. But the path from architecture to impact must remain evidence-led. Claims around additional years of healthy life, healthcare savings, productivity improvement or national economic impact should be earned through real-world validation rather than assumed from the model. The opportunity for QLS–ABI is therefore both ambitious and concrete: start by making health information more understandable; prove that better understanding leads to better decisions; prove that better decisions produce better outcomes; and then scale those outcomes into a trusted longevity platform. If that progression can be demonstrated, QLS–ABI would not need to invent the longevity economy. The economy is already emerging. Its opportunity would be to provide part of the intelligence infrastructure through which that economy operates.

Author: Trang Phan
QLS–ABI Longevity™ — Strategic Framework for Healthy-Longevity Intelligence

Evidence status: The demographic and market statistics above are externally sourced. QLS–ABI architecture and proposed applications are derived from Trang Phan's source framework. Proposed clinical, healthspan, cost-saving and macroeconomic effects remain hypotheses until independently validated.